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Abstract
Objective: We evaluated the effects of peanut consumption on lipid profiles,
atherogenic index of plasma (AIP) and CHD risk in hypercholesterolaemic men.
Design: Randomised crossover clinical trial.
Setting: Participants were randomly assigned to two groups. They were asked to
consume peanut supplements (about 77 g) with their habitual diet for 4 weeks.
Subjects: Fifty-four hypercholesterolaemic men with total cholesterol (TC) con-
centrations between 200 and 350mg/dl.
Results: Compared with the habitual diet, peanut supplementation of the habitual
diet significantly reduced TC/HDL cholesterol (HDL-C) ratio (mean 1 (SE 0?3)
P50?001) and LDL cholesterol (LDL-C)/HDL-C ratio (mean 0?7 (SE 0?2); P50?001).
Peanut consumption increased HDL-C (mean 6?1 (SE 1?5) mg/dl; P,0?001) and total
antioxidant capacity (TAC) (mean 1?2 (SE 0?6) U/mL P50?04). In addition, peanut
consumption significantly reduced the AIP (mean 0?1 (SE 0?03) P50?01) and CHD
estimated risk over 10 years based on systolic and diastolic blood pressures (mean
1?4% (SE 0?5%) P50?004 and mean 2?2% (SE 0?5%) P,0?001, respectively).
Conclusions: Short-term peanut consumption might improve lipid profiles, the AIP
and CHD risk in free-living hypercholesterolaemic men.
Keywords
Peanut
Habitual diet
Coronary heart disease
Atherogenic index of plasma
Regular consumption of nuts is beneficial to cardiovas-
cular health. Data from the Adventist Health Study and
Nurses’ Health Study show that higher nut consumption
is associated with reduced risk of coronary artery dis-
ease(1,2). In addition, other epidemiological studies have
shown that frequent nut consumption decreases the risk
of CHD, with adjusted relative risk reductions approach-
ing 50% in subjects who consume 4–5 servings per week
than those who have little or no intake(3–4).
Peanuts are rich source of Mg, folate, fibre, a-toco-
pherol, Cu, arginine and resveratrol. All of these com-
pounds have been shown to reduce CHD risk in various
ways, and this suggests that peanut consumption might
benefit those at risk for CHD. However, most studies to
date have been performed in either healthy or hyperch-
olesterolaemic subjects in combination with low-fat diet.
O’Byrne et al.(5) reported a decrease of total cholesterol
(TC) and LDL cholesterol (LDL-C) in hypercholester-
olaemic, postmenopausal women on a low total fat, low
SFA and high MUFA diet for 6 months. Kris-Etherton
et al.(6) showed beneficial effects of peanut consumption
on blood lipid concentrations when consumption was
combined with a high MUFA, low SFA diet in normocho-
lesterolaemic subjects. In both of these studies, MUFA intake
largely substituted for SFA intake. This raises the question of
whether the observed shifts in lipid profiles were due to the
increase in dietary MUFA or to the reduction of SFA con-
sumption, and thus the role of peanut consumption is not
clear. Alper and Mattes(7) reported that a moderate increase
in MUFA intake without a concomitant decrease in SFA did
not appear sufficient to decrease TC and LDL-C in normo-
cholesterolaemic individuals, and they showed that peanut
consumption may have beneficial effects on diet composi-
tion even when the background diet is not controlled. In
order to further define the role of peanut consumption in
the reduction of CHD risk factors, we observed the lipid
profiles of hypercholesterolaemic men who began to con-
sume peanuts but made no other changes to their usual diet.
We analysed the atherogenic index of plasma (AIP) for each
subject, which has been defined as a novel marker of
plasma atherogenicity. It increases in people at higher risk
for CHD and may be an important tool for analysing the
results of clinical trials(8). In addition, we estimated CHD risk
to determine the overall effect of peanut consumption in
hypercholesterolaemic men(9).
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Experimental methods
The present study was conducted in Tehran, Iran, in 2006,
and was approved by the Research Council and the
Ethical Committee of the National Nutrition and Food
Technology Research Institute of Shaheed Beheshti
University of Medical Sciences, Tehran, IR of Iran.
The subjects were volunteers and were recruited to
the study through announcement fliers sent to the
Tehran University Hospital employees. Eligible indivi-
duals were male adults, 25–65 years of age, with TC levels
of 200–350mg/dl and mean TAG levels lower than
400mg/dl. Exclusion criteria included acute or chronic
diseases (diabetes, kidney, liver and thyroid diseases;
cancer; or the presence of inflammatory or infectious
disease), consumption of vitamin supplements, hormone
therapy or medications that might have influenced the
study variables (e.g. antihypertensive and antilipidemic
agents administered in the 4 months preceeding the
study), recent history of weight gain or loss ($9 kg)
within the past 6 months, very atypical diet, rigorous
exercise programme, allergy or aversion to nuts, habitual
consumption of more than 70 g of nuts per week, cigar-
ette smokers and first-degree family history of CHD.
Sixty hypercholesterolaemic men met the above criteria
and agreed to take part in the present study. All partici-
pants provided informed written consent. Participants
were randomised between two diet sequences for 4-week
periods – habitual diet and habitual diet supplemented
with peanuts. Thirty participants first followed the habi-
tual diet for 4 weeks and then supplemented their diet
with peanuts for the next 4 weeks; thirty subjects fol-
lowed the same diets in reverse order. Because diet-
induced lipoprotein changes stabilise in ,4 weeks, we
incorporated a washout period of 4 weeks between diets.
During the peanut supplementation period, subjects were
asked to consume a daily allowance of peanuts equiva-
lent to approximately 20% of each subject’s mean energy
intake in addition to their habitual diet. Freshly roasted,
lightly salted peanuts were packaged in separate bags in
three different weights. Individuals whose energy intake
was in the lowest tertile received 60 g of peanuts per day,
those in the middle tertile recieved 77 g per day, and the
highest tertile received 93 g per day. The nutrient com-
position of peanuts per 100 g is as follows: protein 25?7 g,
fat 52?6 g and fibre 4 g. The fatty-acid composition was
21% SFA (10?9% of these were chains shorter than C18
carbons and 10?1% were equal to or longer than C18),
41% MUFA and 38% PUFA (analysed by the Oil Seed
Research and Development Company, Tehran, Iran).
There was no detectable aflatoxin in the peanuts (mea-
sured by immunoaffinity column-liquid chromatography
with post-column derivitisation in the Faroogh Lab,
Tehran, Iran). Participants were given no specific dietary
advice other than to suggest that the peanuts could be
eaten with meals or as snacks. In addition, participants
were given an extra coded bag of peanuts to share with
family and friends to improve compliance. Compliance
was assessed using 24 h diet recalls at three separate time
points during the habitual diet and peanut-supplemented
habitual diet periods, and, because peanuts are a parti-
cularly rich source of MUFA, serum concentration of
MUFA was measured as a biological marker of adherence
to the peanut-supplemented diet.
Dietary intake
Three 24 h recalls were collected by a dietitian at 1-week
intervals in each diet period for all participants. The
recalls were reviewed for accuracy and completeness.
Food intake was calculated by converting household
measures and portion sizes to grams intake. Each food
item was coded according to the prescribed protocol and
entered into a MSACCESS database. Energy and the
nutrient content of each diet was determined using the
Iranian, modified food composition table(10). Three-day
food and nutrient intakes for each period were averaged
and these values were reported as the mean intake of
different food groups and nutrients. To estimate the
amount of energy displacement caused by the peanut
supplement, we calculated displacement as follows(11):
½ðenergy in habitual diet þ peanut energyÞ
 energy in peanut-supplement diet  100
peanut energy
Measurements
The weight of each subject was measured to the nearest
100g with a digital scale while the subjects were minimally
clothed and not wearing shoes. Height was measured in a
standing position, without shoes, using a tape measure
while the shoulders were in a normal state. All measure-
ments were made by the same person. The physician
measured each subject’s blood pressure and obtained a
medical history, including detailed information about med-
ication and nutrient supplement usage. Blood samples were
obtained by venepuncture before and after each diet period.
Each blood sample was taken between 07.00 and 09.00
hours after 12h fasting period. Samples were centrifuged
30–45min after collection. Plasma samples were stored at
(2808C) and analysed at the end of the study. TC and
TAG were measured using an enzymatic colorimetric
method (Pars Azmoun Co., Tehran, Iran). HDL cholesterol
(HDL-C) and LDL-C were quantified by the direct method
(Shanghai Rongsheng Biotech Co. Ltd, Shanghai, China).
The sensitivity of the assays for TC, TAG, HDL-C and LDL-C
were 3, 1, 1 and 2mg/dl, respectively. Oxidised LDL
(Ox-LDL ELISA, Mercodia AB, Uppsala, Sweden) and total
antioxidant capacity (TAC) were measured with colorimetric
kits (Cayman, Ann Arbor, MI, USA); the sensitivity of each
of these kits was 1mU/l and 1U/ml, respectively. Inter-
and intra-assay coefficients of variation for all tests were
,10%. AIP was calculated as the log transformation of
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(TAG/HDL-C), with each value expressed in molar con-
centrations. Finally, CHD risk estimation is defined as the
percentage likelihood of a cardiac event over a period of
10 years. We used the Cardiac Risk Assessor V98.02 software
based on age, sex, systolic and diastolic blood pressures
(SBP and DBP, respectively), TC and HDL-C.
Statistical analysis
The arithmetic mean value of the three diet recalls from
each diet period was calculated, and a paired t test was
used to compare results from the habitual and peanut-
supplemented diet periods. To identify the effects of
peanut consumption on study variables, we calculated
the peanut effect with the formula [(EP2BP)2 (EH2
BH)], where EP is the value at the end of the peanut-
supplemented diet period; BP is the value just before the
peanut-supplemented diet period; EH is the value at the
end of the habitual diet period and BH is the value just
before the habitual diet period. We performed a one-
sample Student’s t test, of which the null hypothesis is that
the population means of this quantity equals zero. This
equation simply shows the effects of peanut consump-
tion on the variables. We calculated relative changes by
‘Peanut effect3 100/baseline’, in which ‘baseline’ is the
average baseline value before the peanut-supplemented
diet and before the habitual diet. To examine whether
there was any carryover, we performed appropriate
repeated-measures ANOVA. Pearson’s correlation co-
efficient was used to assess relationships between con-
tinuous variables. Results are presented as mean values
and their standard errors. All statistical analyses were
performed with Statistical Package for the Social Sciences
statistical software package version 10?0 (SPSS Inc.,
Chicago, IL, USA).
Results
Two subjects lost interest in the study within a few weeks
and withdrew, and four other subjects withdrew due to
unforeseen travel. Ultimately, fifty-four men completed
the study. The participants had a mean age of 43 years
(SE 1?3), a mean BMI of 27?5 kg/m2 (SE 0?5) and mean
serum cholesterol of 254mg/dl (SE 4). According to par-
ticipant reports, compliance with peanut ingestion was
96%. This was supported by a 24?5% (P5 0?02) increase
in measured serum MUFA concentration in these subjects
while they were on the peanut-supplemented diet than
on their habitual diet. Daily peanut consumption was well
tolerated by all subjects. The only reported side-effect
was transient dizziness reported by four subjects. Dietary
intake of participants during the two periods, based on
the mean consumption from the three separate 24h dietary
recalls, is shown in Table 1. There were no differences in
Table 1 Mean daily intake of dietary nutrients and diet composition separated by diet periods
Habitual diet Peanut-supplemented diet
Mean SE Mean SE P value*
n 54?0 54?0 –
Peanut (g) 0?0 77?0 2?0 ,0?001
Energy (kJ) 10 676 284 12 251 335 ,0?001
Carbohydrate (% of energy) 59?0 0?7 52?0 0?7 ,0?001
Protein (% of energy) 13?1 0?3 13?2 0?2 0?13
Plant protein (% of energy) 6?1 0?1 8?0 0?1 ,0?001
Animal protein (% of energy) 7?0 0?3 5?2 0?3 ,0?001
Total fat (% of energy) 27?9 0?6 34?8 0?6 ,0?001
SFA (% of energy) 9?5 0?3 10?0 0?3 0?003
MUFA (% of energy) 11?7 0?3 14?4 0?3 ,0?001
PUFA (% of energy) 6?6 0?2 10?3 0?2 ,0?001
Cholesterol (mg) 250?0 12?0 222?0 15?0 0?13
Fibre (g) 21?0 0?9 29?0 1?0 ,0?001
a-Tocopherol (mg) 13?7 0?5 19?8 0?6 ,0?001
Folate (mg) 266?0 9?0 380?0 11?0 ,0?001
Cu (mg) 1?6 0?08 2?0 0?06 ,0?001
Zn (mg) 13?1 0?4 14?7 0?4 0?001
Mg (mg) 410?0 15?0 548?0 18?0 ,0?001
Food groups
Total grains (g/d) 654?0 26?0 629?0 26?0 0?27
Vegetables (g/d) 263?0 16?0 254?0 19?0 0?68
Fruits (g/d) 298?0 32?0 326?0 31?0 0?49
Meat (g/d) 118?0 8?0 109?0 9?0 0?3
Eggs (g/d) 17?0 3?0 18?0 3?0 0?95
Dairy products (g/d) 402?0 31?0 317?0 26?0 0?01
Fats (g/d) 43?0 2?0 42?0 2?0 0?57
Sweets (g/d) 13?0 3?0 11?0 2?0 0?71
Beverages (ml/d) 966?0 56?0 979?0 56?0 0?77
*P for comparison between the habitual diet and the peanut-supplemented diet by paired t test.
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food groups consumed in the two diet periods (other
than peanuts), except for dairy products.
When subjects changed from their habitual diet to the
peanut-supplemented diet, the intakes of MUFA, PUFA,
fibre, plant protein, a-tocopherol, Cu, folate, Zn, and Mg
all significantly increased (Table 1) and the intakes of
animal protein decreased (all P, 0?001). Body weight
and blood pressure were stable throughout the study.
There were no changes in TC, LDL-C or TAG; but there
was a 17% increase in HDL-C and reductions in TC/HDL-C
and LDL-C/HDL-C ratios (13% for both), which are
shown in Table 2.
The effects of peanut consumption on biomarkers of
oxidative stress, AIP and CHD risk are shown in Table 3.
Peanut supplementation increased TAC of serum by 13%.
In addition, peanut consumption reduced AIP by 35%.
Finally, peanut consumption reduced CHD risk, which is
defined as the percentage likelihood of a cardiac event
over a period of 10 years by 14% and 24% based on SBP
and DBP, respectively. There was no evidence of a carry-
over effect between periods.
Discussion
The present study shows that the addition of peanuts to
the diet, without any other dietary modification, can
favourably modify lipid profiles, AIP and estimated risk of
CHD in hypercholesterolaemic men.
When peanuts were consumed in addition to the sub-
jects’ usual diet, their energy and fat intake increased,
but significant changes in lipid profiles occurred. TC and
LDL-C did not change, but HDL-C increased significantly.
This suggests that increasing MUFA and PUFA intake
without decreasing SFA is not sufficient to decrease TC
and LDL-C, but it can increase HDL-C and improve
TC/HDL-C and LDL-C/HDL-C ratios in a cardioprotective
manner(12–13). Sheridan et al.(14) showed similar effects of
pistachio nuts on the lipid profiles of free-living human
subjects with primary, moderate hypercholesterolaemia.
TAC considers the cumulative action of all antioxidants
present in plasma and body fluids and provides an inte-
grated measurement rather than the simple sum of mea-
surable antioxidants. Low TAC is a risk factor for ischaemic
heart disease(15). In the present study, peanut consumption
increased serum TAC by 13%. In addition to TAC, the
AIP was recently proposed as a marker of plasma ather-
ogenicity, and was shown to be increased in subjects at
higher risk for CHD. AIP is also inversely correlated with
LDL particle size(8). The association of TAG and HDL-C in
this simple ratio theoretically reflects the balance between
risk and protective lipoprotein forces. In the present study,
peanut consumption reduced AIP, and this is correlated
with the estimated CHD risk (r5 0?54, P, 0?001).
Estimated CHD risk is defined as the likelihood that a
cardiac event will occur over a period of 10 years, and is T
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calculated based on blood pressure, TC, LDL-C, HDL-C
and TAG concentrations. In the present study, most of
the variables used to calculate CHD did not change
significantly. However, HDL-C increased significantly,
and because HDL-C is a very strong inverse predictor of
cardiovascular events(16), the estimated CHD risk was
reduced.
When subjects began to supplement their usual diet
with peanuts, their intake of MUFA, PUFA, fibre, plant
protein, a-tocopherol, Cu, folate, Zn and Mg increased
and the intake of animal protein decreased. These nutri-
ent changes are similar to the dietary changes recom-
mended to prevent CVD and other chronic diseases(17).
Despite daily peanut consumption (, 77 g, or 1884 kJ of
energy), no weight gain was observed in the study sub-
jects. This may be due to several factors. During peanut
consumption, subjects spontaneously commented on the
high satiety value of the peanuts(18) and reported diffi-
culties with consumption of habitual diet. In the present
study, peanut displaced 12% of the normal energy intake
of the subjects, and these subjects inadvertently com-
pensated by decreasing carbohydrate intake by 6%.
Another factor may be that faecal fat and energy loss is
great with consumption of whole peanuts(19). In the
present study, nearly all of the subjects complained of
increased frequency of daefecation and fatty stools.
Finally, as shown in some studies, peanuts may enhance
energy expenditure(20). More studies are required to
determine the long-term effects of peanut consumption
on lipid profiles, metabolic changes and CHD risk in
hypercholesterolaemic men. However, the data presented
here suggest that it might be possible to reduce CHD risk
factors using a single, simple intervention such as increas-
ing peanut consumption in hypercholesterolaemic men. In
summary, these results indicate that short-term peanut
consumption in free-living hypercholesterolaemic men
might favourably improve lipid profiles, AIP and CHD risk.
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